Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape-Reference-Cited by-同舟云学术

Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape

Published:2022-09-14 Issue:41 Volume:43 Page:4227-4228
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Pedicino Daniela¹^ORCID,Volpe Massimo²^ORCID

Affiliation:

1. Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli—IRCCS , Largo A. Gemelli 8, Rome 00168 , Italy

2. Cardiology Department, Sapienza University of Rome, Sant’Andrea Hospital , Via di Grottarossa 1035-1039, Rome 00189 , Italy

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/43/41/4227/48744693/ehac502.pdf

Reference12 articles.

1. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial;Kim;Lancet,2022

2. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

3. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;J Am Coll Cardiol,2019

4. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Cholesterol Treatment Trialists’ (CTT) Collaboration;Lancet,2010

5. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants;Wang;Lancet Diabetes Endocrinol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hope springs eternal: are we yet ready for a novel paradigm shift in lipid-lowering therapy in primary prevention?;European Journal of Preventive Cardiology;2024-04-10

2. Bibliometric analysis of monoclonal antibodies for atherosclerosis;Human Vaccines & Immunotherapeutics;2023-10-31